Aurinia (AUPH) | Stock Overview & Key Data
Aurinia Performance Comparison
Stock Range
Today's Range
Low: $11.74
High: $12.15
on August 21, 2025
52 Week Range
Low: $6.34
High: $12.53
on August 21, 2024
on August 18, 2025
All-Time High: $33.97 on November 1, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.6B
EPS
0.43
P/E Ratio (TTM)
28.53
Forward P/E
22.72
P/B Ratio
4.86
PEG Ratio
22.72
Div. Yield
N/A
ROE
17.33%
Beta
1.237
Debt to Equity
24.41
Financial Highlights
Profitability
Gross Margin
89.84%
Operating Margin
28.85%
Profit Margin
23.31%
Returns and Earnings
Return on Assets (TTM)
7.69%
Return on Equity (TTM)
17.33%
EBITDA
$103.5M
Net Income (TTM)
$60.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.85
Quarterly Revenue Growth (YoY)
22.40%
Quarterly Earnings Growth (YoY)
2,879.60%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Aurinia AUPH | 1.62B Small-cap | -0.08% | 40.14% | 44.84% | 52.33% | 37.74% | 78.70% | 56.48% | -12.27% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| Cg Oncology CGON | 1.99B Small-cap | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% | -29.82% | -25.83% | -25.83% |
| Adaptive ADPT | 1.99B Small-cap | -2.24% | 22.50% | 38.94% | 52.72% | 104.04% | 159.88% | 20.52% | -69.05% |
| Vericel VCEL | 1.80B Small-cap | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% | -28.10% | 30.92% | 116.49% |
Ownership & Short Interest
Insider Ownership
9.31%
Institutional Ownership
45.41%
Shares Short
9M
Short Ratio
4.41
Short % of Shares Outstanding
7.62%
Average 10-Day Volume
3M
Average 90-Day Volume
3M
Aurinia Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Aurinia would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AUPH's 52-week high and low?
- In the last 52 weeks, Aurinia reached a high of $12.53 (on August 18, 2025) and a low of $6.34 (on August 21, 2024).
- What is the market cap and P/E ratio for AUPH?
- Curious about Aurinia's size and valuation? Its market capitalization stands at 1.62B. When it comes to valuation, the P/E ratio (trailing twelve months) is 28.53, and the forward P/E (looking ahead) is 22.72.
- Does AUPH pay dividends? If so, what's the yield?
- As for dividends, Aurinia isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Aurinia's main competitors or similar companies to consider before investing?
When looking at Aurinia, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% Cg Oncology
CGON1.99B Healthcare Biotechnology -29.82% -25.83% Adaptive
ADPT1.99B Healthcare Biotechnology 159.88% 20.52% Vericel
VCEL1.80B Healthcare Biotechnology -28.10% 30.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aurinia Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Aurinia's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.33%, the Debt to Equity ratio from the most recent quarter is 24.41, and its Gross Profit Margin stands at 89.84%.
- What is the recent revenue and earnings growth for AUPH?
- Looking at Aurinia's growth, its revenue over the trailing twelve months (TTM) was $260M. Compared to the same quarter last year (YoY), quarterly revenue grew by 22.40%, and quarterly earnings saw a YoY growth of 2,879.60%.
- How much of AUPH stock is held by insiders and institutions?
- Wondering who owns Aurinia stock? Company insiders (like executives and directors) hold about 9.31% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 45.41%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.